<SEC-DOCUMENT>0001683168-18-001771.txt : 20180625
<SEC-HEADER>0001683168-18-001771.hdr.sgml : 20180625
<ACCEPTANCE-DATETIME>20180625083013
ACCESSION NUMBER:		0001683168-18-001771
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20180619
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20180625
DATE AS OF CHANGE:		20180625

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			AETHLON MEDICAL INC
		CENTRAL INDEX KEY:			0000882291
		STANDARD INDUSTRIAL CLASSIFICATION:	LABORATORY ANALYTICAL INSTRUMENTS [3826]
		IRS NUMBER:				133632859
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			0331

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37487
		FILM NUMBER:		18916050

	BUSINESS ADDRESS:	
		STREET 1:		9635 GRANITE RIDGE DRIVE, SUITE 100
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92123
		BUSINESS PHONE:		858-459-7800

	MAIL ADDRESS:	
		STREET 1:		9635 GRANITE RIDGE DRIVE, SUITE 100
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92123

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BISHOP EQUITIES INC
		DATE OF NAME CHANGE:	19930602
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>aethlon_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>FORM 8-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CURRENT REPORT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Pursuant to Section&nbsp;13 or 15(d)&nbsp;of
the Securities Exchange Act of 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Date of Report (Date of earliest event reported)
June 19, 2018</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 12pt"><B>AETHLON
MEDICAL, INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact name of registrant as specified in
its charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR>
    <TD STYLE="vertical-align: top; width: 32%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Nevada</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(State or other jurisdiction</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">of incorporation)</P></TD>
    <TD STYLE="vertical-align: bottom; width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 32%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">000-21846</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Commission<BR>
        File Number)</P></TD>
    <TD STYLE="vertical-align: bottom; width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 32%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">13-3632859</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(IRS Employer</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Identification Number)</P></TD></TR>
</TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 45%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 10%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 45%; font-size: 10pt">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">8910 University Center Lane, Suite 660</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">San Diego, California</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Address of principal executive offices)</P></TD>
    <TD STYLE="vertical-align: bottom; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">92122</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Zip Code)</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Registrant&rsquo;s telephone number, including
area code: (858) 459-7800</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><U>Not applicable</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Former name or former address, if changed
since last report.)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction
A.2 below):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR>
    <TD STYLE="vertical-align: top; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 97%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Written communications pursuant to Rule&nbsp;425 under the Securities Act (17 CFR 230.425)</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Soliciting material pursuant to Rule&nbsp;14a-12 under the Exchange Act (17 CFR 240.14a-12)</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement communications pursuant to Rule&nbsp;14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement communications pursuant to Rule&nbsp;13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Indicate by checkmark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&sect;230.405 of this chapter) or Rule 12b-2
of the Securities Exchange Act of 1934</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Emerging growth company.&nbsp;&nbsp;&#9744;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">If an emerging growth company, indicate
by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section&nbsp;13(a) of the Exchange Act.&nbsp;&nbsp;&#9744;</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Value: 1; Name: PageNo; Options: Hidden --><!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>FORWARD-LOOKING STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This Form 8-K and other reports filed by Registrant from time
to time with the Securities and Exchange Commission (collectively, the &quot;Filings&quot;) contain or may contain forward-looking
statements and information that are based upon beliefs of, and information currently available to, Registrant's management as well
as estimates and assumptions made by Registrant's management. When used in the Filings the words &quot;anticipate,&rdquo; &quot;believe,&quot;
&quot;estimate,&quot; &quot;expect,&quot; &quot;future,&quot; &quot;intend,&quot; &quot;plan&quot; or the negative of these terms
and similar expressions as they relate to Registrant or Registrant's management identify forward-looking statements. Such statements
reflect the current view of Registrant with respect to future events and are subject to risks, uncertainties, assumptions and other
factors relating to Registrant's industry, Registrant's operations and results of operations and any businesses that may be acquired
by Registrant. Should one or more of these risks or uncertainties materialize, or should the underlying assumptions prove incorrect,
actual results may differ significantly from those anticipated, believed, estimated, expected, intended or planned.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Although Registrant believes that the expectations reflected
in the forward-looking statements are reasonable, Registrant cannot guarantee future results, levels of activity, performance or
achievements. Except as required by applicable law, including the securities laws of the United States, Registrant does not intend
to update any of the forward-looking statements to conform these statements to actual results.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>ITEM 5.02 Appointment of a Director</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On June 19, 2018, Guy Cipriani joined the Board of Directors
of Aethlon Medical, Inc. (the &ldquo;Company&rdquo;). Mr. Cipriani meets the requirements to serve as an independent director of
the Company under the applicable Nasdaq Rules.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Mr. Cipriani is a business executive with nearly 20 years of
experience in the pharmaceutical and biotech industries. His extensive background includes corporate and business development,
strategic planning, alliance management, and product development activities. He has successfully completed over twenty deals of
various types, including commercialization agreements, development agreements, discovery collaborations, distribution agreements
across multiple therapeutic areas including cardiovascular, infectious disease, oncology, and CNS.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Currently (and since July 2017), Mr. Cipriani serves as Chief
Business Officer at Microbion Corporation, a company focused on the development of a new class of antibiotic therapies for difficult
to treat and resistant infections. His business and corporate development responsibilities at Microbion include securing partnerships
and raising dilutive and non-dilutive capital for the company&rsquo;s promising clinical-stage pipeline. From July 2012 to July
2017, he served as Vice President of Business Development at Cascadian Therapeutics where he was responsible for licensing-in several
promising pipeline candidates and generating external interest in the company&rsquo;s clinical-stage pipeline to set the stage
for future strategic transactions. Prior to that role, Mr. Cipriani served as Vice President of Business Development at Cardiome
Pharma Corp. where he led the negotiation of a US $800 million global development and co-commercialization licensing deal with
Merck &amp; Company in 2009 around the company&rsquo;s lead Phase 3 cardiovascular program. Prior to Cardiome, Mr. Cipriani served
as Senior Director of Business Development for TransForm Pharmaceuticals, Inc., where his efforts helped facilitate the company&rsquo;s
acquisition by Johnson and Johnson for $230 million in 2005. Mr. Cipriani began his pharmaceutical industry career at Eli Lilly
&amp; Company as a member of their Corporate Business Development team where he completed multiple in-licensing and out-licensing
transactions for commercial, clinical and preclinical state assets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Mr. Cipriani holds a B.S.E.E., High Honors from Rochester Institute
of Technology and an MBA from the Kellogg Graduate School of Management at Northwestern University. The Company has determined
that Mr. Cipriani is a valuable asset to its Board due to his vast experience in business and transactional development and execution
in the life sciences industry.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>ITEM 9.01 Exhibits</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Exhibit 99.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <A HREF="aethlon_ex9901.htm">Press Release, dated June 25, 2018</A></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pursuant to the requirements of the Securities Exchange Act
of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 51%">&nbsp;</TD>
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 46%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">AETHLON MEDICAL, INC.</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: white 3pt solid">&nbsp;</TD>
    <TD STYLE="vertical-align: top; border-bottom: white 3pt solid">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:&nbsp;<U>/s/ James B. Frakes&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">James B. Frakes</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated: June 25, 2018</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Financial Officer</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>aethlon_ex9901.htm
<DESCRIPTION>GUY CIPRIANI JOINS AETHLON MEDICAL BOARD OF DIRECTORS
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">EXHIBIT 99.1</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><IMG SRC="image_001.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Guy Cipriani Joins Aethlon Medical&rsquo;s
Board of Directors</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">SAN DIEGO, CA, June 25, 2018 -- Aethlon
Medical, Inc. (Nasdaq: AEMD), a therapeutic technology company focused on unmet needs in global health and biodefense, today announced
the appointment of Guy Cipriani to its Board of Directors. Mr. Cipriani qualifies as an independent director under the Nasdaq Rules.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&ldquo;We are very pleased to have Guy join the Aethlon team,&rdquo;
stated Aethlon Medical CEO, Jim Joyce.&quot; Guy will further strengthen the business development expertise of our board and his
history of business partnering success will be an asset to our endeavors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&ldquo;It&lsquo;s an honor to join the Aethlon Medical board
and I look forward to contributing my expertise and perspective to help advance the Hemopurifier and future candidate therapies
to the marketplace,&rdquo; stated Mr. Cipriani.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Mr. Cipriani is a business executive with nearly 20 years of
experience in the pharmaceutical and biotech industries. His extensive background includes corporate and business development,
strategic planning, alliance management, and product development activities. He has successfully completed over twenty deals of
various types, including commercialization agreements, development agreements, discovery collaborations, distribution agreements
across multiple therapeutic areas including cardiovascular, infectious disease, oncology, and CNS.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Currently, Mr. Cipriani serves as Chief Business Officer at
Microbion Corporation, a company focused on the development of a new class of antibiotic therapies for difficult to treat and resistant
infections. His business and corporate development responsibilities at Microbion include securing partnerships and raising dilutive
and non-dilutive capital for the company&rsquo;s promising clinical-stage pipeline. Prior to Microbion he served as VP of Business
Development at Cascadian Therapeutics where he was responsible for licensing-in several promising pipeline candidates and generating
external interest in the company&rsquo;s clinical-stage pipeline to set the stage for future strategic transactions. Prior to that
role, Mr. Cipriani served as VP of Business Development at Cardiome Pharma Corp. where he led the negotiation of a US $800 million
global development and co-commercialization licensing deal with Merck &amp; Company in 2009 around the company&rsquo;s lead Phase
3 cardiovascular program. Prior to Cardiome, Mr. Cipriani served as Sr. Director of Business Development for TransForm Pharmaceuticals,
Inc., where his efforts helped facilitate the company&rsquo;s acquisition by Johnson and Johnson for $230 million in 2005. Mr.
Cipriani began his pharmaceutical industry career at Eli Lilly &amp; Company as a member of their Corporate Business Development
team where he completed multiple in-licensing and out-licensing transactions for commercial, clinical and preclinical state assets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Mr. Cipriani holds a B.S.E.E., High Honors from Rochester Institute
of Technology and an MBA from the Kellogg Graduate School of Management at Northwestern University. The Company has determined
that Mr. Cipriani is a valuable asset to its Board due to his vast experience in business and transactional development and execution
in the life sciences industry.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>About Aethlon Medical, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Aethlon Medical is focused on addressing unmet needs in global
health and biodefense. The Aethlon Hemopurifier&reg; is a first-in-class therapeutic device designed to address life-threatening
viral infections. The United States Food and Drug Administration (FDA) has designated the Hemopurifier&reg; as a Breakthrough Device
related to the treatment of life-threatening viruses that are not addressed with approved therapies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In collaboration with leading government and non-government
research institutes, Aethlon has validated the ability of the Hemopurifier&reg; to capture a broad-spectrum of pandemic influenza
viruses, mosquito-borne viruses and deadly hemorrhagic viruses. Based on its use to treat Ebola virus, the Hemopurifier&reg; was
named a &ldquo;Top 25 Invention&rdquo; and one of the &ldquo;Eleven Most Remarkable Advances in Healthcare,&quot; by TIME Magazine.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Aethlon is also investigating the potential therapeutic use
of the Hemopurifier&reg; to reduce the presence of tumor-derived exosomes, which contribute to immune-suppression and the spread
of metastasis in cancer patients. Additionally, Aethlon is the majority owner of Exosome Sciences, Inc. (ESI), which is focused
on the discovery of exosomal biomarkers to diagnose and monitor cancer and neurological disorders, including Alzheimer's disease
(AD) and Chronic Traumatic Encephalopathy (CTE). Additional information can be found online at www.AethlonMedical.com and www.ExosomeSciences.com.
You can also connect with us on Twitter, LinkedIn, Facebook and Google+.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Forward Looking Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>This press release contains forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 that involve risks
and uncertainties. Statements containing words such as &quot;may,&quot; &quot;believe,&quot; &quot;anticipate,&quot; &quot;expect,&quot;
&quot;intend,&quot; &quot;plan,&quot; &quot;project,&quot; &quot;will,&quot; &quot;projections,&quot; &quot;estimate,&quot; or
similar expressions constitute forward-looking statements. Such forward-looking statements are subject to significant risks and
uncertainties and actual results may differ materially from the results anticipated in the forward-looking statements. Factors
that may contribute to such differences include, without limitation, the Company's ability to maintain its listing on the Nasdaq
Capital Market, or any other national securities exchange, that the Company or its subsidiary will not be able to commercialize
its products, that the FDA will not approve the initiation or continuation of the Company's clinical programs or provide market
clearance of the Company's products, the Company's ability to raise capital when needed, the Company's ability to complete the
development of its planned products, the Company's ability to manufacture its products either internally or through outside companies,
the impact of government regulations, patent protection on the Company's proprietary technology, product liability exposure, uncertainty
of market acceptance, competition, technological change, and other risk factors. The foregoing list of risks and uncertainties
is illustrative, but is not exhaustive. Additional factors that could cause results to differ materially from those anticipated
in forward-looking statements can be found under the caption &quot;Risk Factors&quot; in the Company's Annual Report on Form 10-K
for the year ended March 31, 2018, and in the Company's other filings with the Securities and Exchange Commission. Except as may
be required by law, the Company does not intend, nor does it undertake any duty, to update this information to reflect future events
or circumstances.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Company Contact:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Jim Frakes</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Chief Financial Officer</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Aethlon Medical, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">858-459-7800 extension 3300</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Jfrakes@aethlonmedical.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>





</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !( ,$# 2(  A$! Q$!_\0
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M+H<I7U-R ?\ T&O***]N&4X:*U3?S_R/.EC:S>CL>S6/Q=T:=PMY:7=IG^+
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MDWI'\?Z1I1P\82<UU_ ****XCI"BBB@ HHHH **** #%&*** $P*7 HHH 3
MI<444 )@4M%% !BC%%% !@5'/;PW,+0SQ)+$XPR.H8$>X-%% '%ZG\+/#U\[
M/;+/8N>T#Y7_ +Y.?TK%;X-1;OEUR0+[VP)_]"HHKJCF&)@K*;,)86C)W<2_
M8_"+1H'#7EW=W>/X<B-3^7/ZUVVFZ1I^D6WD:?9Q6T?<1KC/U/4_C116=3$U
6JW\239<*-.'PJQ=HHHK$T"BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
